2002/03/1 5 15:39	űΝ	USPAT; US-PGPUB; EPO; JPO; DER MENT	adj max) or (arachis adj hypogaea) or (bandeirea adj simplicifolia) same lectin	Н Н	L9	BRS	9
PUE; EPO; 2002/03/: DER WENT , 5 15:38	EPO;	USPAT; US-PGPUE; JPO; DERW	or (ar (aea) adj	2804	L8	BRS :	ω
USPAT; US-PGPUE; EPO; 2002/03/1 JPO; DERWENT 5 15:38	T; GPUE; DERWE	USPAT; US-PGP JPO; D	(1 or 2) same (6)	N	L7	BRS	7
USPAT; US-PGPUE; EPO; 2002/03/ JPO; DEFWENT 5 15:37	T; GPUE; EPO; DERWENT	USPAT; US-PGPUE JPO; DER	lectin same (galactose or galactosyl or aceylgalactosamine)	546		BRS	0
USPAT; US-PGPUE; EPO; 2002/03/ JPO; DEFWENT 5 15:37	T; GPUE; EPO; DEFWENT	USPAT; US-PGP JPO; D	(1 or 2) same (3 or 4)	7	L5	BRS	Л
USPAT; US-PGPUI; EPO; 2002/03/ JPO; DEFWENT 5 15:34	AT; PGPUI; EPO; DEFWENT	USPAT; US-PGP JPO; D	(galactose adj binding) same 3	61	L4	BRS	44
USPAT; US-PGPUI; EPO; 2002/03/1 JPO; DEIWENT 5 15:33	Σ	USPAT; US-PGP JPO; D	lectin	9706	L3	BRS	ω
USPAT; US-PGPUI; EPO; 2002/03/1 JPO; DEIWENT 5 15:32	T; GPUI; EPO; DEIWENT	USPAT; US-PGP JPO; D	botulinum adj (toxin or neurotoxin)	366	L2	BRS	N
USPAT; US-PGPUI; EPO; 2002/03/1 JPO; DEI WENT 5 15:32	AT; PGPUI; EPO; DEI WENT	USPAT; US-PGP JPO; D	clostridial adj neurotoxin	55	L1	BRS	Н
DEs Time Stamp	DI s		Search Text	Hits	#	Туре	

	·	-	·						
0			2002/03/1 5 15:40	USPAT; US-PGPUE; EPO; JPO; DEFWENT	(lectin same (arachis adj hypogaea)) same (clostridial adj neurotoxin)	0	L13	BRS	13
0			2002/03/1 5 15:39	USPAT; US-PGPUI; EPO; JPO; DEIWENT	lectin same (arachis adj hypogaea)	56	L12	BRS	12
0			2002/03/1 5 15:39	USPAT; US-PGPUI; EPO; JPO; DEIWENT	(lectin same (recombinant or modified)) same (botulinum adj (toxin or neurotoxin))	0	L11	BRS	11
0			2002/03/1 5 15:39	USPAT; US-PGPUI; EPO; JPO; DELWENT	((erythrina or (glycine adj max) or (arachis adj hypogaea) or (bandeirea adj simplicifolia)) same lectin) same (clostridial adj neurotoxin)	0	L10	BRS	10
R H	Err or Def ini tio	Com men	Time Stamp	DI s	Search Text	Hits	#	Туре	

=> d his

(FILE 'HOME' ENTERED AT 15:42:12 ON 15 MAR 2002)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT

15:42:43 ON 15 MAR 2002

- L1 832 S (CLOSTRIDIAL NEUROTOXIN)
- L2 18172 S (BOTULINUM TOXIN) OR (BOTULINUM NEUROTOXIN)
- L3 141534 S LECTIN
- L4 15375 S L3 (P) (GALACTOSE OR GALACTOSYL OR

ACETYLGALACTOSAMINE)

- L5 2 S (L1 OR L2) AND L4
- L6 2 DUPLICATE REMOVE L5 (0 DUPLICATES REMOVED)
- L7 9561 S L3 (P) (RECOMBINANT OR MODIF?)
- L8 4 S (L1 OR L2) AND L7
- L9 2 DUPLICATÉ REMOVE L8 (2 DUPLICATES REMOVED)
- L10 1 S L9 NOT L6

 $=> \log y$

FILE 'HOME' ENTERED AT 15:42:12 ON 15 MAR 2002

=> file medline caplus biosis embase scisearch agricola

COST IN U.S. DOLLARS

SINCE FILE ENTRY

TOTAL SESSION

FULL ESTIMATED COST

0.15

0.15

FILE 'MEDLINE' ENTERED AT 15:42:43 ON 15 MAR 2002

FILE 'CAPLUS' ENTERED AT 15:42:43 ON 15 MAR 2002 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE 'BIOSIS' ENTERED AT 15:42:43 ON 15 MAR 2002 COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 15:42:43 ON 15 MAR 2002 COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 15:42:43 ON 15 MAR 2002 COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'AGRICOLA' ENTERED AT 15:42:43 ON 15 MAR 2002

=> s (clostridial neurotoxin) 832 (CLOSTRIDIAL NEUROTOXIN)

=> s (botulinum toxin) or (botulinum neurotoxin)

18172 (BOTULINUM TOXIN) OR (BOTULINUM NEUROTOXIN)

-> = lectin

141534 LECTIN

=> s 13 (p) (galactose or galactosyl or acetylgalactosamine) 15375 L3 (P) (GALACTOSE OR GALACTOSYL OR ACETYLGALACTOSAMINE)

=> s (11 or 12) and 14

L5 2 (L1 OR L2) AND L4

=> duplicate remove 15

PROCESSING COMPLETED FOR L5

2 DUPLICATE REMOVE L5 (0 DUPLICATES REMOVED) L6

=> d 16 1-2 ibib abs

ANSWER 1 OF 2 CAPLUS COPYRIGHT 2002 ACS 2000:706999 CAPLUS

ACCESSION NUMBER: DOCUMENT NUMBER:

133:261538

TITLE:

Use of a lectin or lectin conjugate for modulation of

C-fiber activity, and therapeutic use thereof

INVENTOR (S):

-Foster, Keith-Alan; Chaddock, John-Andrew; Quinn,

Conrad Padraig

HBM

PATENT ASSIGNEE(S):

Microbiological Research Authority, UK

SOURCE:

PCT Int. Appl., 62 pp. CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

	PATENT NO.				KIND DATE			APPLICATION NO. DATE										
	WO 2000057897						2000	1005		W	0 20	00-G	B124	7	2000	0331		
		W:	ΑE,	AG,	AL,	AM,	AT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	CA,	CH.	CN.	CR.
															GH,			
															LR,			
															RO,			
															υz,			
							KG,						,	•	•	•	•	,
		RW:	GH,	GM,	KΕ,	LS,	MW,	SD,	SL,	SZ,	TZ,	UG,	ZW,	AT,	BE,	CH,	CY,	DE,
															SE,			
			CG,	CI,	CM,	GΑ,	GN,	GW,	ML,	MR,	NE,	SN,	TD,	TG		•		•
	EΡ	1165	114							EP 2000-914295 20000331								
		R:	ΑT,	ΒE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,
							FI,							•	•	•	•	
PRIORITY APPLN. INFO.: GB 1999-7429 A 19990331																		
									1	VO 20	000-0	3B124	1 7	W :	20000	331		
ΔR	WO 2000-GB1247 W 20000331 AB The invention relates to the treatment of pair and to completely that																	

The invention relates to the treatment of pain and to compds. that

modulate C-fiber activity. In particular, the invention relates to the use of a lectin in the manuf. of a medicament for modulation of C-fiber neuron activity, and to lectin conjugates. The lectin conjugates comprise

a lectin coupled to a peptide or protein, wherein the peptide or protein is substantially free of Clostridial neurotoxin enzyme activity. The invention also concerns methods for manufg. the conjugates.

The compds. and compns. described have particular application in the treatment of diseases of which C-fiber activity is a component. Such uiseases include pain, inflammation, psoriasis and other C-fiber related conditions.

REFERENCE COUNT:

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2002 ACS

5

ACCESSION NUMBER:

1999:249106 CAPLUS

DOCUMENT NUMBER:

130:276767

TITLE:

Conjugates of galactose-binding

lectins and clostridial neurotoxins as analgesics

INVENTOR(S):

Duggan, Michael John; Chaddock, John Andrew

PATENT ASSIGNEE(S):

The Speywood Laboratory Limited, UK; Microbiological

Research Authority PCT Int. Appl., 50 pp.

SOURCE: CODEN: PIXXD2

DOCUMENT TYPE:

Patent

1

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT_INFORMATION:

```
PATENT NO.
                      KIND DATE
                                           APPLICATION NO. DATE
      -----
                                           -----
     WO 9917806
                      A1
                            19990415
                                           WO 1998-GB3001
                                                            19981007
         W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
             DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE,
             KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,
             MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,
             TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM
         RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
             CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     AU 9893574
                       A1
                            19990427
                                           AU 1998-93574
                                                            19981007
     AU 741456
                       B2
                            20011129
     ZA 9809138
                            19990527
                                           ZA 1998-9138
                       Α
                                                            19981007
     EP 996468
                       A1
                            20000503
                                           EP 1998-946571
                                                            19981007
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI
     JP 2001518522
                            20011016
                                           JP 2000-514674
                                                            19981007
PRIORITY APPLN. INFO.:
                                        GB 1997-21189
                                                       A 19971008
                                        WO 1998-GB3001
                                                       W 19981007
     A class of novel agents that are able to modify nociceptive afferent
AB
     function is provided. The agents may inhibit the release of
     neurotransmitters from discrete populations of neurons and thereby reduce
     or preferably prevent the transmission of afferent pain signals from
     peripheral to central pain fibers. They comprise a galactose
     -binding lectin linked to a deriv. of a clostridial
     neurotoxin. The deriv. of the clostridial
     neurotoxin comprises the L-chain, or a fragment thereof, which
     includes the active proteolytic enzyme domain of the light (L) chain,
     linked to a mol. or domain with membrane-translocating activity. The
     agents may be used in or as pharmaceuticals for the treatment of pain,
     particularly chronic pain.
REFERENCE COUNT:
                               THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
                         6
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT
=> d his
     (FILE 'HOME' ENTERED AT 15:42:12 ON 15 MAR 2002)
     FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT
     15:42:43 ON 15 MAR 2002
L1
            832 S (CLOSTRIDIAL NEUROTOXIN)
L2
          18172 S (BOTULINUM TOXIN) OR (BOTULINUM NEUROTOXIN)
L3
         141534 S LECTIN
          15375 S L3 (P) (GALACTOSE OR GALACTOSYL OR ACETYLGALACTOSAMINE)
L4
L5
              2 S (L1 OR L2) AND L4
L6
              2 DUPLICATE REMOVE L5 (0 DUPLICATES REMOVED)
=> s 13 (p) (recombinant or modif?)
          9561 L3 (P) (RECOMBINANT OR MODIF?)
L7
=> s (11 or 12) and 17
L8
             4 (L1 OR L2) AND L7
```

^{=&}gt; duplicate remove 18

HBM

DUPLICATE PREFERENCE IS 'CAPLUS, EMBASE, SCISEARCH' KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n PROCESSING COMPLETED FOR L8

2 DUPLICATE REMOVE L8 (2 DUPLICATES REMOVED)

=> s 19 not 16

SOURCE:

L10 1 L9 NOT L6

=> d 110 1 ibib abs

L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS ACCESSION NUMBER: 2002:75297 CAPLUS

DOCUMENT NUMBER: 136:113889

TITLE: Modification of biological properties of protein

toxins by stepwise iodination

AUTHOR(S): Heneine, Luiz G. D.; Heneine, Ibrahim F.

CORPORATE SOURCE:

Research & Development Laboratory, Ezequiel Dias

Foundation (FUNED), Belo Horizonte, 30510-050, Brazil Journal of Toxicology, Toxin Reviews (2001), 20(3 &

4), 209-228

CODEN: JTTRD9; ISSN: 0731-3837

PUBLISHER: Marcel Dekker, Inc. DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. By gradual incorporation of stable iodine into toxins and whole

venoms it is possible to abolish completely the physiol., lesional, and lethal properties of the native components. The properties of iodinated antigens and from antibodies generated by these detoxified derivs. are presented. The hapten is incorporated into tyrosyl and histidyl residues.

The derivs. can be obtained in <1 h. Within the same batch of protein, there is a determinable stoichiometric ratio hapten/protein to achieve the

desired modified properties of the deriv. The iodinating solns. are easy to prep., can be accurately standardized, and have unlimited side-effects, local or systemic, were obsd., even with prolonged use of the derivs. The method was applied to toxic components and whole venom

the scorpion Tityus serrulatus, and the hypertensive, bradipneic, oliguric, lesional, lethal, and cytotoxic effects were completely abolished. Polyclonal antibodies generated by these iodinated antigens neutralized the virulent effects of native components and reversed the .alpha. effects of the whole venom in frog sciatic nerves. They conferred

active immunization in mice, rats, guinea pigs, goats, horses, and pigeons. Crotoxin and the whole venom of Crotalus durrissus terrificus lost the lesional and lethal activity but conserved the immunogenic capacity. They produced antibodies against the native components, giving also vaccinal protection. While the virulent crotalic antigens had a cytotoxic activity, the iodinated antigens were highly mitogenic with human white cells. Repetitive sublethal doses of scorpionic, crotalic, and bothropic venoms led invariably to an amyloid-like deposit in tissues whereas the iodinated samples were ineffective. Allergenic exts. of Schistosoma mansoni can be transformed into anallergic derivs. that

of

suum can be completely deactivated with iodination but conserved immunol. competence. Cholera, tetanus, and botulinum toxins, as iodinated toxoids, had their lesional and lethal capacity completely avoided. Physiol. proteins with strong biol. activity can also be rendered innocuous. Iodinated insulin lost its capacity to lower blood glucose levels but induced high avidity antibodies in guinea pigs and rabbits. By iodination, kallikrein can be turned unable to contract rat uterus and to liberate kinins from kinninogen. Modified tonin do not increase the blood pressure in rats. Aq. exts. of Leptospira

and L. icterohaemorrhagiae after iodination were innocuous to hatched eggs, and immunogenic in mice and rabbits. A lectin from Macrotylema axillare lost the hemaglutination capacity with only 75% of iodine satn. The deriv. was highly immunogenic in rabbits. Heavy iodination can transform self-antigens in non-self, generating antibodies in same species animals. All derivs. obtained were stable, did not show any reversion to toxicity, generated antibodies against the native antigens, and gave active protection when injected in animals. The injections were also apparently painless. The time gap between the accident and the administration of antibodies is discussed for systemic and local effects. A new schedule for immunization, only feasible with toxoided venoms, is presented. It is based on a clonal expansion induced

by a small dose, followed by an exponential satn. dose of the same toxoid.

The attainment of higher levels of protecting antibodies against the

native antigen in the generated sera is unmatched by other procedures. Data for practical use of iodination is presented.

REFERENCE COUNT:

93 THERE ARE 93 CITED REFERENCES AVAILABLE FOR

THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

=> d his

(FILE 'HOME' ENTERED AT 15:42:12 ON 15 MAR 2002)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 15:42:43 ON 15 MAR 2002 L1832 S (CLOSTRIDIAL NEUROTOXIN) L2 18172 S (BOTULINUM TOXIN) OR (BOTULINUM NEUROTOXIN) L3141534 S LECTIN L415375 S L3 (P) (GALACTOSE OR GALACTOSYL OR ACETYLGALACTOSAMINE) L5 2 S (L1 OR L2) AND L4 2 DUPLICATE REMOVE L5 (0 DUPLICATES REMOVED) L6 9561 S L3 (P) (RECOMBINANT OR MODIF?) L7 L8 4 S (L1 OR L2) AND L7 2 DUPLICATE REMOVE L8 (2 DUPLICATES REMOVED) L9 L10 1 S L9 NOT L6

=> log y COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY 35.35	SESSION 35.50
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	-1.86	SESSION- -1.86